Evidence map›Paper›PMID 39062468›Full record

ArticleBiomolecules2024

In Silico Comparative Analysis of Ivermectin and Nirmatrelvir Inhibitors Interacting with the SARS-CoV-2 Main Protease.

Yuri Alves de Oliveira Só, Katyanna Sales Bezerra, Ricardo Gargano, Fabio L L Mendonça, Janeusa Trindade Souto, Umberto L Fulco, Marcelo Lopes Pereira Junior, Luiz Antônio Ribeiro Junior

Abstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Biomolecules, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Yuri Alves de Oliveira SóInstitute of Physics, University of Brasília, Brasília 70910-900, Brazil.ORCID 0000-0002-5569-0868
Katyanna Sales BezerraDepartment of Biophysics and Pharmacology, Federal University of Rio Grande do Norte, Natal 59078-570, Brazil.ORCID 0000-0003-1019-9642
Ricardo GarganoInstitute of Physics, University of Brasília, Brasília 70910-900, Brazil.ORCID 0000-0003-3823-7436
Fabio L L MendonçaDepartment of Electrical Engineering, College of Technology, University of Brasília, Brasília 70910-900, Brazil.ORCID 0000-0001-7100-7304
Janeusa Trindade SoutoDepartment of Microbiology and Parasitology, Biosciences Center, Federal University of Rio Grande do Norte, Natal 59064-741, Brazil.ORCID 0000-0002-4115-4829
Umberto L FulcoDepartment of Biophysics and Pharmacology, Federal University of Rio Grande do Norte, Natal 59078-570, Brazil.ORCID 0000-0002-4528-9878
Marcelo Lopes Pereira JuniorDepartment of Electrical Engineering, College of Technology, University of Brasília, Brasília 70910-900, Brazil.ORCID 0000-0001-9058-510X
Luiz Antônio Ribeiro JuniorInstitute of Physics, University of Brasília, Brasília 70910-900, Brazil.ORCID 0000-0001-7468-2946

Funding

Coordenação de Aperfeicoamento de Pessoal de Nível Superior 88887.691997/2022-00Foundation for Research Support of the Federal District 0193-00001807/2023-16.National Council for Scientific and Technological Development 302236/2018
6 · The paper itself

Abstract

Exploring therapeutic options is crucial in the ongoing COVID-19 pandemic caused by SARS-CoV-2. Nirmatrelvir, which is a potent inhibitor that targets the SARS-CoV-2 M

Indexed as

Antiviral AgentsCoronavirus 3C ProteasesCOVID-19 Drug TreatmentIvermectinMolecular Docking SimulationMolecular Dynamics SimulationSARS-CoV-2Binding SitesHumansLactamsLeucineNitrilesProlineProtease InhibitorsProtein BindingSulfonamidesAntiviral AgentsCoronavirus 3C ProteasesIvermectinLactamsLeucinenirmatrelvirNitrilesProlineProtease InhibitorsSulfonamidesIvermectinmain protease (Mpro)molecular dockingmolecular dynamicsNirmatrelvirSARS-CoV-2

Identifiers

PMID39062468
PMCPMC11274663

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.